{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T04:21:10Z","timestamp":1729657270797,"version":"3.28.0"},"reference-count":19,"publisher":"Baishideng Publishing Group Inc.","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"abstract":"<jats:p>Helicobacter pylori  (H. pylori ) infections may cause chronic gastritis, peptic ulcer disease, gastric cancers, and other conditions outside of the gastrointestinal tract. Hence, it is important to diagnose and treat it early. H. pylori  is resistant to certain drugs in traditional eradication therapy, so alternative therapy protocols are needed, such as high-dose amoxicillin dual therapy (HDADT). This article aims to comment on a recent paper by Costigan et al  in the World Journal of Clinical Cases . In this study, the authors recruited 139 patients diagnosed with H. pylori , all treated with HDADT. Of these, 93 were treatment-na\u00efve and 46 had received at least one alternative treatment in the past. Four weeks after the end of the treatment, the urea breath test was administered to estimate the eradication rate. The total eradication rate was 56% (78\/139), 62% for the treatment-na\u00efve arm and 43% for the previous treatment arm, thus indicating a lower success rate for the arm that had previously received a different treatment regimen. In conclusion, a therapeutic approach with first-line HDADT may potentially be a better treatment, but the results are not sufficient to recommend the use of this regimen in a country with high levels of dual resistance.<\/jats:p>","DOI":"10.12998\/wjcc.v12.i35.6859","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T12:54:33Z","timestamp":1729601673000},"page":"6859-6863","source":"Crossref","is-referenced-by-count":0,"title":["Role of high-dose amoxicillin dual therapy for <i>Helicobacter pylori<\/i> eradication in an Irish cohort: A prospective study"],"prefix":"10.12998","volume":"12","author":[{"given":"Raffaele","family":"Palmirotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Cafiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marica","family":"Colella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","unstructured":"Santacroce L, Cagiano R, Del Prete R, Bottalico L, Sabatini R, Carlaio RG, Prejbeanu R, Vermesan H, Dragulescu SI, Vermesan D, Motoc A, Losacco T. Helicobacter pylori infection and gastric MALTomas: an up-to-date and therapy highlight. Clin Ter 2008; 159: 457-462"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1302-3_1"},{"key":"B3","unstructured":"Zullo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A. Gastric MALT lymphoma: old and new insights. Ann Gastroenterol 2014; 27: 27-33"},{"key":"B4","unstructured":"World Health Organization.   International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 60. 1994; 1-241. Available from: https:\/\/publications.iarc.fr\/78"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309252"},{"key":"B6","unstructured":"HPRA Drug Safety Newsletter.   Fluoroquinolone antibiotics-EU review advises restrictions for certain infections and warns of rare but serious long lasting adverse reactions. Available from: https:\/\/www.hpra.ie\/docs\/default-source\/publications-forms\/newsletters\/hpra-drug-safety-newsletter-edition-91.pdf?sfvrsn=7"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i16.2773"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119433"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294403"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4877-9"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12843"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpede.2022.02.001"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202406_36460"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S219069"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-6-545"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2020.18974"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1096103"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i35\/6859.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i35\/6859.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T12:55:27Z","timestamp":1729601727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i35\/6859.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":19,"journal-issue":{"issue":"35"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v12.i35.6859","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}